Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $163.6 million.

  • Oncology Institute's Liabilities and Shareholders Equity fell 868.61% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.1 million, marking a year-over-year decrease of 1455.18%. This contributed to the annual value of $172.7 million for FY2024, which is 1745.51% down from last year.
  • As of Q3 2025, Oncology Institute's Liabilities and Shareholders Equity stood at $163.6 million, which was down 868.61% from $159.8 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Liabilities and Shareholders Equity registered a high of $283.8 million during Q3 2022, and its lowest value of $159.8 million during Q2 2025.
  • Over the past 5 years, Oncology Institute's median Liabilities and Shareholders Equity value was $206.5 million (recorded in 2022), while the average stood at $208.0 million.
  • As far as peak fluctuations go, Oncology Institute's Liabilities and Shareholders Equity soared by 20970.03% in 2021, and later plummeted by 2306.15% in 2023.
  • Over the past 5 years, Oncology Institute's Liabilities and Shareholders Equity (Quarter) stood at $203.4 million in 2021, then increased by 28.62% to $261.7 million in 2022, then decreased by 20.04% to $209.2 million in 2023, then decreased by 17.46% to $172.7 million in 2024, then fell by 5.27% to $163.6 million in 2025.
  • Its last three reported values are $163.6 million in Q3 2025, $159.8 million for Q2 2025, and $164.0 million during Q1 2025.